References
- BlackDMCummingsSRKarpfDBRandomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesLancet1996348153515418950879
- CummingsSRBlackDMThompsonDEEffect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention TrialJAMA1998280207720829875874
- WellsGACranneyAPetersonJAlendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal womenCochrane Database Syst Rev.2008231CD00115518253985
- The WHO Scientific GroupPrevention and management of osteoporosisWorld Health Organ Tech Rep Ser200392186109
- OrimoHShirakiMHayashiYEffects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosisCalcif Tissue Int1994543703768062152
- KushidaKShirakiMNakamuraTThe efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis:a randomized, double-blind, active-controlled, double-dummy trialCurrent Therapeutic Research.2002639606620
- KushidaKShirakiMNakamuraTAlendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up studyJ Bone Miner Metab20042246246815316867
- BoneHGHoskingDDevogelaerJPAlendronate Phase III Osteoporosis Treatment Study GroupTen years’ experience with alendronate for osteoporosis in postmenopausal womenN Engl J Med20043501189119915028823
- OrimoHJapanese guideline for prevention and treatment of osteoporosisLife Science2006
- OrimoHSugiokaYFukunagaMDiagnostic criteria of primary osteoporosisJ Bone Miner Metab199816139150
- OrimoHHayashiYFukunagaMDiagnostic criteria for primary osteoporosis: year 2000 revisionJ Bone Miner Metab20011933133711685647
- ShirakiMKushidaKFukunagaMA double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosisOsteoporos Int19991018319210525709
- UchidaSTaniguchiTShimizuTTherapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized studyJ Bone Miner Metab20052338238816133688
- IwamotoJTakedaTSatoYUzawaMEarly changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with one-year response of lumbar bone mineral density to alendronate in Japanese postmenopausal women with osteoporosisJ Bone Miner Metab20052323824215838627
- NishizawaYNakamuraTOhtaHCommittee on the Guidelines for the Use of Biochemical Markers of Bone Turnover in Osteoporosis Japan Osteoporosis Society. Guidelines for the use of biochemical markers of bone turnover in osteoporosisJ Bone Miner Metab2005239710415750686
- SirisESChenYTAbbottTABone mineral density thresholds for pharmacological intervention to prevent fracturesArch Intern Med20041641108111215159268
- IwamotoJTakedaTSatoYEffects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosisClin Rheumatol20042338338915278749
- TucciJRToninoRPEmkeyRDEffect of three years of oral alendronate treatment in postmenopausal women with osteoporosisAm J Med19961014885018948272
- ShirakiMFukuchiMKiriyamaTAlfacalcidol reduces accelerated bone turnover in elderly women with osteoporosisJ Bone Miner Metab20042235235915221494
- ShirakiMItoHOrimoHThe ultra long-term treatment of senile osteoporosis with 1 alpha-hydroxyvitamin D3Bone Miner1993202232348490326